Loading
Azacitidine primes leukaemia cells for death; venetoclax removes the BCL-2 shield. Together they roughly doubled remissions in older AML.
This combination pairs venetoclax with the hypomethylating agent azacitidine in acute myeloid leukaemia, chiefly in older patients who cannot have intensive chemotherapy. Azacitidine lowers MCL-1 and induces NOXA, which increases the leukaemia cells' dependence on BCL-2, and venetoclax then blocks BCL-2 and removes that last shield, driving intrinsic apoptosis. The phase 3 VIALE-A trial showed an overall survival benefit and a higher remission rate than azacitidine alone, and the regimen is now available fully orally with decitabine-cedazuridine plus venetoclax, supported by ASCERTAIN-V and introduced in 2026. The duration of venetoclax within each cycle is being shortened from 28 days to 14 to reduce cytopenias without losing efficacy.
Shares Decitabine + cedazuridine (oral), VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, VIALE-A, Acute myeloid leukaemia in older or unfit patients.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, VIALE-A, Venetoclax, Acute myeloid leukaemia.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Acute myeloid leukaemia.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Azacitidine, Venetoclax, Acute myeloid leukaemia.